{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:43:42Z","timestamp":1761864222288,"version":"3.41.2"},"reference-count":33,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001234","name":"McNair Medical Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001234","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001234","name":"Robert and Janice McNair Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001234","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune checkpoint inhibitor\u2013associated diabetes mellitus (ICI-DM) is a known immune-related adverse event (irAE) following treatment with programmed cell death protein 1 (PD-1), with a reported 0.9% incidence. We hereby present the first case, to our knowledge, of ICI-DM following ICI use in a human immunodeficiency virus (HIV) patient. In this case, a 48-year-old man with HIV stable on highly active antiretroviral therapy (HAART) was diagnosed with Hodgkin lymphoma and initiated treatment with the PD-1 inhibitor nivolumab. His lymphoma achieved complete response after 5 months. However, at month 8, he reported sudden polydipsia and polyuria. Labs revealed a glucose level of 764 mg\/dL and glycated hemoglobin A1c (HbA1c) of 7.1%. Low C-peptide and elevated glutamic acid decarboxylase 65 (GAD65) antibody levels confirmed autoimmune DM, and he was started on insulin. Major histocompatibility complex class II genetic analysis revealed homozygous HLA DRB1*03-DQA1*0501-DQB1*02 (DR3-DQ2), which is a known primary driver of genetic susceptibility to type 1 DM. Autoimmune DM has been reported as an ICI-associated irAE. However, patients with immunocompromising conditions such as HIV are usually excluded from ICI trials. Therefore, little is known about such irAEs in this population. In this case, risk of ICI-DM as an irAE was likely increased by several factors including family history, a high-risk genetic profile, islet-related immunologic abnormalities, active lymphoma, and HIV infection with a possible immune reconstitution event. Clinicians should maintain a high index of suspicion for development of irAEs associated with ICI, particularly as use of these therapies broadens. Thorough investigation for presence of higher-risk features should be conducted and may warrant inclusion of pre-therapy genetic and\/or autoantibody screening.<\/jats:p>","DOI":"10.1210\/jendso\/bvaa150","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T18:21:05Z","timestamp":1605205265000},"source":"Crossref","is-referenced-by-count":5,"title":["Checking the Checkpoint Inhibitors: A Case of Autoimmune Diabetes After PD-1 Inhibition in a Patient with HIV"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-0350","authenticated-orcid":false,"given":"Michael S","family":"Hughes","sequence":"first","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA"},{"name":"Michael E. DeBakey VA Medical Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0012-3193","authenticated-orcid":false,"given":"Massimo","family":"Pietropaolo","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhuri M","family":"Vasudevan","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA"},{"name":"Michael E. DeBakey VA Medical Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3935-4116","authenticated-orcid":false,"given":"Marco","family":"Marcelli","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA"},{"name":"Michael E. DeBakey VA Medical Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0338-0083","authenticated-orcid":false,"given":"Ha","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"issue":"1","key":"2020111212123380600_CIT0001","first-page":"40","article-title":"The 2018 Nobel Prize in medicine for breakthroughs in targeting immune checkpoint inhibitors: a brief perspective","volume":"2","author":"Rios","year":"2019","journal-title":"Antib Ther."},{"issue":"1","key":"2020111212123380600_CIT0002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1172\/JCI131194","article-title":"Time to dissect the autoimmune etiology of cancer antibody immunotherapy","volume":"130","author":"Dougan","year":"2020","journal-title":"J Clin Invest."},{"issue":"1","key":"2020111212123380600_CIT0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers."},{"issue":"9","key":"2020111212123380600_CIT0004","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet Med."},{"issue":"8","key":"2020111212123380600_CIT0005","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes."},{"issue":"12","key":"2020111212123380600_CIT0006","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor-associated diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care."},{"issue":"1","key":"2020111212123380600_CIT0007","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care."},{"issue":"2","key":"2020111212123380600_CIT0008","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.clml.2017.12.008","article-title":"HIV-related refractory hodgkin lymphoma: a case report of complete response to nivolumab","volume":"18","author":"Chang","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"10","key":"2020111212123380600_CIT0009","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1210\/jc.2018-01430","article-title":"PD-1 inhibitor immune-related adverse events in patients with preexisting endocrine autoimmunity","volume":"103","author":"Akturk","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2020111212123380600_CIT0010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ecl.2010.05.011","article-title":"Epidemiology of type 1 diabetes","volume":"39","author":"Maahs","year":"2010","journal-title":"Endocrinol Metab Clin North Am."},{"key":"2020111212123380600_CIT0011","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mam.2014.12.004","article-title":"Immunogenetics of type 1 diabetes mellitus","volume":"42","author":"Morran","year":"2015","journal-title":"Mol Aspects Med."},{"issue":"4","key":"2020111212123380600_CIT0012","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2337\/db07-1331","article-title":"HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families","volume":"57","author":"Erlich","year":"2008","journal-title":"Diabetes."},{"issue":"8","key":"2020111212123380600_CIT0013","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0198-8859(02)00421-4","article-title":"The HLA class I A locus affects susceptibility to type 1 diabetes","volume":"63","author":"Noble","year":"2002","journal-title":"Hum Immunol."},{"issue":"10","key":"2020111212123380600_CIT0014","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care."},{"issue":"9","key":"2020111212123380600_CIT0015","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2337\/db18-1351","article-title":"Autoantibodies directed toward a novel IA-2 variant protein enhance prediction of type 1 diabetes","volume":"68","author":"Acevedo-Calado","year":"2019","journal-title":"Diabetes."},{"key":"2020111212123380600_CIT0016","doi-asserted-by":"crossref","first-page":"1847430","DOI":"10.1155\/2018\/1847430","article-title":"Association of autoimmune thyroid disease with anti-GAD antibody ELISA test positivity and risk for insulin deficiency in slowly progressive type 1 diabetes","volume":"2018","author":"Katahira","year":"2018","journal-title":"J Diabetes Res."},{"issue":"6","key":"2020111212123380600_CIT0017","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.metabol.2010.07.025","article-title":"Clinical and genetic characteristics of patients with autoimmune thyroid disease with anti-islet autoimmunity","volume":"60","author":"Moriguchi","year":"2011","journal-title":"Metabolism."},{"issue":"1","key":"2020111212123380600_CIT0018","first-page":"37","article-title":"Frequency of pancreatic beta-cell autoimmunity markers in patients with autoimmune thyroid disease","volume":"68","author":"Primo","year":"2008","journal-title":"Medicina (B Aires)."},{"issue":"6167","key":"2020111212123380600_CIT0019","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science."},{"issue":"9","key":"2020111212123380600_CIT0020","doi-asserted-by":"crossref","first-page":"a007765","DOI":"10.1101\/cshperspect.a007765","article-title":"Do MHCII-presented neoantigens drive type 1 diabetes and other autoimmune diseases?","volume":"2","author":"Marrack","year":"2012","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"4","key":"2020111212123380600_CIT0021","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1006\/bcmd.2001.0442","article-title":"The dual association between lymphoma and autoimmunity","volume":"27","author":"Ehrenfeld","year":"2001","journal-title":"Blood Cells Mol Dis."},{"issue":"15","key":"2020111212123380600_CIT0022","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1097\/00002030-199715000-00009","article-title":"Clinical implications of autoantibodies in HIV infection","volume":"11","author":"Massabki","year":"1997","journal-title":"Aids."},{"key":"2020111212123380600_CIT0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2018.01.005","article-title":"HIV infection and its effects on the development of autoimmune disorders","volume":"129","author":"Vega","year":"2018","journal-title":"Pharmacol Res."},{"issue":"5","key":"2020111212123380600_CIT0024","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","article-title":"Immunogenic neoantigens derived from gene fusions stimulate T cell responses","volume":"25","author":"Yang","year":"2019","journal-title":"Nat Med."},{"issue":"2","key":"2020111212123380600_CIT0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003495-200868020-00004","article-title":"Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management","volume":"68","author":"Dhasmana","year":"2008","journal-title":"Drugs."},{"issue":"4","key":"2020111212123380600_CIT0026","doi-asserted-by":"crossref","first-page":"e5769","DOI":"10.1097\/MD.0000000000005769","article-title":"Autoimmune diseases and HIV infection: a cross-sectional study","volume":"96","author":"Virot","year":"2017","journal-title":"Medicine (Baltimore)."},{"issue":"8","key":"2020111212123380600_CIT0027","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1210\/jc.2010-0055","article-title":"Autoimmune diabetes in HIV-infected patients on highly active antiretroviral therapy","volume":"95","author":"Takarabe","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2020111212123380600_CIT0028","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11904-011-0106-4","article-title":"Role of PD-1 in HIV pathogenesis and as target for therapy","volume":"9","author":"Porichis","year":"2012","journal-title":"Curr HIV\/AIDS Rep."},{"key":"2020111212123380600_CIT0029","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","article-title":"PD-1\/PD-L and autoimmunity: A growing relationship","volume":"310","author":"Zamani","year":"2016","journal-title":"Cell Immunol."},{"issue":"11","key":"2020111212123380600_CIT0030","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/QAD.0000000000001849","article-title":"Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency","volume":"32","author":"Evans","year":"2018","journal-title":"AIDS."},{"issue":"7","key":"2020111212123380600_CIT0031","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol."},{"issue":"6","key":"2020111212123380600_CIT0032","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12094-018-1981-6","article-title":"Cancer immunotherapy of patients with HIV infection","volume":"21","author":"Gonzalez-Cao","year":"2019","journal-title":"Clin Transl Oncol."},{"issue":"11","key":"2020111212123380600_CIT0033","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer."}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/4\/12\/bvaa150\/34279680\/bvaa150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/4\/12\/bvaa150\/34279680\/bvaa150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T18:21:24Z","timestamp":1605205284000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaa150\/5978891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaa150","relation":{},"ISSN":["2472-1972"],"issn-type":[{"type":"electronic","value":"2472-1972"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,11,12]]},"article-number":"bvaa150"}}